In this article, we will look at the 12 Best Strong Buy Stocks to Invest in According to Wall Street.
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data, and more.
His take on the situation is that the problem is that the core PCE remains stuck around 3%, and it’s really “tying” the central bank’s hands. He does not anticipate aggressive rate cuts unless the labor market really deteriorates.
READ ALSO: Stocks On The Rise: 12 Best Stocks to Invest in Right Now and 12 Affordable Biotech Stocks to Invest In Now.
He added that if there is going to be a reason for a pullback in the stock market, it is likely going to be the AI tech trade exhausting itself, along with the realization that we are in what he calls a “rate-tweaking cycle” instead of a “rate-cutting cycle.”
With these trends in view, let’s look at the best strong buy stocks to invest in according to Wall Street.
Our Methodology
We used stock screeners and TipRanks to make a list of the best Strong Buy stocks and selected the top 12 with the highest analyst upside potential. We also added the number of hedge fund holders for each stock as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of analyst upside potential.
Note: All data was sourced on September 26.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
12 Best Strong Buy Stocks to Invest in According to Wall Street
12. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)
Analyst Upside: 74.13%
Number of Hedge Fund Holders: 51
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is one of the best strong buy stocks to invest in according to Wall Street. On September 16, William Blair analyst Dylan Becker reiterated a bullish stance on Clearwater Analytics Holdings, Inc. (NYSE:CWAN), giving it a Buy rating without assigning a price target.
The analyst based the optimistic rating on the company’s future potential and strategic positioning, stating that the recent Clearwater Connect 2025 conference exhibited Clearwater Analytics Holdings, Inc.’s (NYSE:CWAN) vision for the creation of the industry’s first unified, end-to-end platform for investment management.
The analyst expects this to address the rising complexity in asset management.
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) provides web-based investment portfolio accounting, reporting, and reconciliation services. The company’s operations are divided into the United States and the Rest of the World geographical segments.
11. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Analyst Upside: 74.25%
Number of Hedge Fund Holders: 28
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, JPMorgan analyst Jessica Fye lowered the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $52 from $53 while keeping an Overweight rating on the shares.
The firm told investors that it updated Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) model to reflect slightly higher spending assumptions.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company’s product candidate, CRN00808, is an oral treatment for acromegaly. It is also developing other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing’s disease.
10. The GEO Group, Inc. (NYSE:GEO)
Analyst Upside: 77.03%
Number of Hedge Fund Holders: 49
The GEO Group, Inc. (NYSE:GEO) is one of the best strong buy stocks to invest in according to Wall Street. On September 17, Noble Financial analyst Joe Gomes maintained a Buy rating on The GEO Group, Inc. (NYSE:GEO) and set a price target of $35.00.
The rating came after The GEO Group, Inc. (NYSE:GEO) announced on September 16 that the Florida Department of Corrections issued “Notices of Intent to Award three managed-only contracts to GEO for the assumption of management and support services at the 985-bed Bay Correctional and Rehabilitation Facility and the 1,884-bed Graceville Correctional and Rehabilitation Facility and for the continuation of management and support services at the 985-bed Moore Haven Correctional and Rehabilitation Facility.”
The GEO Group, Inc. (NYSE:GEO) designs, finances, develops, and supports services for processing centers, secure facilities, and community re-entry facilities. Its operations are divided into the following segments: US Secure, Electronic Monitoring and Supervision, Re-entry, and International Services.
The US Secure Services segment comprises the US-based public-private partnership correction and detention segment, while the Electronic Monitoring and Supervision Services segment offers services in the US.
The International Services segment offers public-private partnership secure services operations in South Africa and Australia, and the Re-entry Services Segment comprises various community-based and re-entry services.
9. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Analyst Upside: 79.20%
Number of Hedge Fund Holders: 58
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 17, Christopher Raymond from Raymond James maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and set a price target of $85.00.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported total revenues of $825 million in fiscal Q2 2025, up 16% year-over-year and up 17% year-over-year at constant currency. GAAP diluted earnings per share (EPS) for the quarter reached $1.23.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
8. Soleno Therapeutics, Inc. (NASDAQ:SLNO)
Analyst Upside: 84.73%
Number of Hedge Fund Holders: 52
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, Wells Fargo analyst Derek Archila reiterated a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $123.00.
Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported that it used $12.6 million of cash in its operating activities during the three months ended June 30, 2025. Management reported that the company had $293.8 million of cash, cash equivalents, and marketable securities as of the end of the quarter.
Management also reported that cash at the end of Q2 “excludes $230 million of gross proceeds that the company raised in July through an underwritten offering of common stock”. Product revenue, net, for the quarter reached $32.7 million.
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics to treat rare diseases. The company focuses on the treatment of neurobehavioral and metabolic disorders. Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).
7. MicroStrategy Incorporated (NASDAQ:MSTR)
Analyst Upside: 89.61%
Number of Hedge Fund Holders: 45
MicroStrategy Incorporated (NASDAQ:MSTR) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 15, Gautam Chhugani from Bernstein maintained a Buy rating on MicroStrategy Incorporated (NASDAQ:MSTR) and set a price target of $600.00.
However, on September 16, Monness analyst Gustavo Gala reiterated a Sell rating on MicroStrategy Incorporated (NASDAQ:MSTR) and set a price target of $175. The same day, TD Cowen also lowered the firm’s price target on the stock to $620 from $640 while keeping a Buy rating on the shares.
The stock’s median price target of $309.06 implies an upside of 89.61% from current levels.
MicroStrategy Incorporated (NASDAQ:MSTR) engages in the development of the Bitcoin network through its operations in technology, financial markets, and advocacy. It is the world’s largest corporate holder of Bitcoin.
6. Legend Biotech Corporation (NASDAQ:LEGN)
Analyst Upside: 127.75%
Number of Hedge Fund Holders: 39
Legend Biotech Corporation (NASDAQ:LEGN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 12, Leonid Timashev from RBC Capital reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a price target of $77.00.
Legend Biotech Corporation (NASDAQ:LEGN) reported CARVYKTI net trade sales of around $439 million in fiscal Q2 2025, with CARVYKTI demonstrating “positive long-term outcomes in the CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 years.”
Management also reported cash and cash equivalents, and time deposits of $1.0 billion as of June 30.
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.
5. Apogee Therapeutics Inc. (NASDAQ:APGE)
Analyst Upside: 148.56%
Number of Hedge Fund Holders: 36
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25, RBC Capital initiated coverage of Apogee Therapeutics Inc. (NASDAQ:APGE) with an Outperform rating and a $60 price target.
The firm expressed optimistic sentiments regarding the company’s potential to deliver clinically differentiated biologics, telling investors in a research note that Apogee Therapeutics Inc.’s (NASDAQ:APGE) early clinical and more recent Phase II atopic dermatitis data exhibited the beneficial properties of APG777 and its combo therapies.
RBC sees considerable revenue opportunities across several inflammation and immunology indications, supporting the optimistic rating.
Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications.
4. Immunovant, Inc. (NASDAQ:IMVT)
Analyst Upside: 174.18%
Number of Hedge Fund Holders: 31
Immunovant, Inc. (NASDAQ:IMVT) is one of the best strong buy stocks to invest in according to Wall Street. On September 3, LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the price target at $50.00.
Similarly, BofA analyst Jason Gerberry maintained a buy rating on the stock but lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $33.
Leerink Partners analyst Thomas Smith also expressed bullish sentiments for Immunovant, Inc. (NASDAQ:IMVT), reiterating a Buy rating with a $52.00 price target.
The analyst consensus rating for Immunovant, Inc. (NASDAQ:IMVT) is a Strong Buy, and the stock’s median price target of $16.23 implies an upside of 174.18% from current levels.
Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).
3. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Analyst Upside: 176.82%
Number of Hedge Fund Holders: 60
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 22, Kristen Kluska from Cantor Fitzgerald reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a price target of $105.00.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported $166 million in total revenue for fiscal Q2 2025, with Crysvita revenue coming up to $120 million and Dojolvi revenue reaching $23 million.
The company reaffirmed its 2025 revenue guidance, with total revenue in the $640 million to $670 million range.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops, acquires, and commercializes novel products to treat genetic diseases. Its product portfolio includes Crysvita, Mepsevii, Dojolvi, and Evkeeza. In 2024, the company expanded its business through four products in five indications worldwide.
2. Vaxcyte, Inc. (NASDAQ:PCVX)
Analyst Upside: 241.38%
Number of Hedge Fund Holders: 44
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best strong buy stocks to invest in according to Wall Street. Goldman Sachs initiated coverage of Vaxcyte, Inc. (NASDAQ:PCVX) on September 12 with a Neutral rating and a $38 price target.
However, Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 16, setting a price target of $163.00.
Similarly, Seamus Fernandez from Guggenheim also reiterated a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 7, setting a $116 price target.
Currently, the analyst consensus on Vaxcyte is a Strong Buy, and the stock’s median price target of $33.98 implies an upside of 241.38% from current levels.
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques.
1. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Analyst Upside: 291.08%
Number of Hedge Fund Holders: 43
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best strong buy stocks to invest in according to Wall Street. On September 22, BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a $125.00 price target.
The analyst based the optimistic rating on the company’s strong position in the obesity and metabolic disease market, reasoning that the recent acquisitions conducted by the large pharmaceutical companies, including the acquisition of Metsera by Pfizer, highlight the strategic significance and high valuation of the companies in the sector.
According to Zelin, Viking Therapeutics, Inc. (NASDAQ:VKTX) is considered one of the few remaining independent industry players that boast an advanced and mature portfolio, factors that make the company an attractive target for acquisitions or partnerships.
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage company that develops therapies for metabolic and endocrine disorders.
While we acknowledge the potential of VKTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VKTX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
